MRSA: A COSTLY AND POTENT SUPERBUG

Facing skyrocketing healthcare costs, the Centers for Medicare and Medicaid Services (CMS) is targeting one of the primary causes: hospital-acquired conditions (HACs). According to the CMS, a HAC is an infection acquired in a hospital by a patient who was admitted for a reason other than that infection. HACs make up a substantial portion of overall healthcare spending, and MRSA is one of the main culprits.

Considereda superbug, MRSA has developed a resistance to most antibiotics and is extremely potent. For example, according to the Pew Charitable Trusts,every year in the U.S. MRSA is responsible for up to $4.2 billion in costs. But the worst cost of all is the human price paid since MRSA is responsible for approximately 80,000 infections and 11,000 deaths annually in the U.S.

NEW MRSA RULES COULD COST HOSPITALS SIGNIFICANTLY

Currently MRSA infection rates aren’t part of the reimbursement equation in Medicare’s Hospital Value-Based Purchasing (VBP) scorecard, but that will change starting Jan. 1, 2017. At that point, MRSA will not only be included in reimbursement calculations as dictated by the Hospital-Acquired Condition Reduction Program, but the weighting of infections will increase as well from 65 percent in 2015 to 85 percent in 2017.

All hospitals nationwide will be impacted by the new MRSA rules, but it will be the worst-performing ones that will be hardest hit financially. Hospitals already face a 1 percent reduction in payments if they are in the bottom 25 percent with regard to HAC prevention — and that’s without MRSA incorporated. With MRSA factored in, hospitals will be facing hundreds of millions of dollars in lost Medicare reimbursements.

This is on top of what it costs to treat MRSA. According to the Centers for Disease Control and Prevention (CDC), MRSA infections are among the highest of all antibiotic-resistant threats. What’s more, treatment can last months and many times patients have to return after the initial discharge. For these reasons, MRSA care in the U.S. can cost up to $60,000 per patient and up to $9.7 billion annually.

NEW YORK CITY HOSPITALS FACING GREATEST FINANCIAL IMPACT

Hospitals across the U.S. will be affected by the updated MRSA calculations, but one of the areas facing the greatest financial impact is New York City since the metro region is home to many of the worst performers in the country. The city’s hospitals, especially those already struggling to contain MRSA, are barely turning a profit, and these looming cuts that represent tens of millions of dollars could put many of them in the red.

For example, looking at hospitals in the three largest U.S. cities, New York City, Los Angeles, and Chicago, it’s clear that New York City will be hardest hit. Even with just the current reimbursement structure that doesn’t include MRSA, for fiscal year 2015, New York City is projected to lose over $26 million in penalties compared to only $9 million for Los Angeles and $8 million for Chicago. Once MRSA is factored in, these losses will skyrocket.

THE SOLUTION: BETTER AIR TREATMENT

MRSA is difficult to remove from an indoor space. It’s also easily spread via respiratory droplets and aerosol tracts, and can live for up to 80 days. It commonly attaches to skin scales of various sizes, and as these scales shed, the larger ones fall to the floor and the smaller ones can waft through the entire length of a hospital ward. When MRSA does settle, the bacteria are generally found on dusty, hard-to-reach surfaces.

Because MRSA travels through the air so effortlessly, the traditional way to remove it is through air filtration. However, conventional HVAC filters only capture large particles and miss the smaller — and deadlier — ones, such as MRSA, other bacteria, viruses, and volatile organic compounds (VOCs). Therefore, a more effective option is photocatalytic oxidation (PCO), which destroys the smallest particles by converting them into carbon dioxide and water.

PCO technology has many benefits. First and foremost, it removes 99.99 percent of the MRSA bacteria in a single pass, as well as other submicron contaminants, including tuberculosis, anthrax, staph, E. coli, endotoxins, mycotoxins, viruses, and other VOCs. Additionally, the oxidation process takes place within the air cleaner so no reactions occur around indoor occupants. The efficient design uses no extra fan energy and the cost-effective technology integrates seamlessly with existing air handling units (AHUs).

THE RESULT: FEWER MRSA INFECTIONS AND AN IMPROVED BOTTOM LINE

The data show that hospitals across the country that utilize PCO technology have significantly fewer MRSA infection rates. On average, hospitals using this technology score 27 points (out of 100) higher compared to those in New York City without such systems. These high-performing hospitals stand to increase their reimbursements with the impending change to the Medicare structure, thus improving their bottom line.

IN SUM

New MRSA rules beginning in 2017 are poised to cost hospitals — especially the worst performers — hundreds of millions of dollars in lost Medicare reimbursements. However, this unfavorable financial scenario can be avoided if hospitals act now and install the right air-treatment technology, such as a PCO system, to eliminate MRSA. Not only will hospitals avoid substantial financial losses, the health of their patients will be significantly enhanced.

Publication date: 4/4/2016

Want more HVAC industry news and information? Join The NEWS on Facebook, Twitter, and LinkedIn today!